Future directions for cancer immunotherapy

Adam Feuerstein, STAT’s senior writer and national biotech columnist, examines some of the most promising areas of cancer immunotherapy research. He’ll explain how a better understanding of tumor biology is helping researchers exploit new immune-based targets, and he’ll explore the different technologies — from CAR-Ts and antibodies to viruses and mRNA — that are being deployed against them.

Speakers: 

• Karen K. Ersland, Ph.D., scientific liaison, research solutions-US region, BD Biosciences (sponsor introduction)
• Adam Feuerstein, senior writer, biotech, STAT